amlodipine has been researched along with Edema in 76 studies
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.
Edema: Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Chlorthalidone is a very effective antihypertensive drug, but it has not been studied prospectively in kidney transplant recipients with hypertension." | 9.24 | Chlorthalidone Versus Amlodipine for Hypertension in Kidney Transplant Recipients Treated With Tacrolimus: A Randomized Crossover Trial. ( Hesselink, DA; Hoorn, EJ; Moes, AD; van den Meiracker, AH; Zietse, R, 2017) |
| "In hypertensive patients not controlled on prior BB and ACEI/ARB therapy, addition of (S)-amlodipine besylate at half the dose of conventional amlodipine provides better tolerability with reduced incidence of peripheral edema, and equal antihypertensive efficacy compared to amlodipine given at usual doses." | 9.22 | Leg edema with (S)-amlodipine vs conventional amlodipine given in triple therapy for hypertension: a randomized double blind controlled clinical trial. ( Ekanayaka, RA; Galappatthy, GK; Galappatthy, P; Sabeer, MI; Waniganayake, YC; Wijethunga, TJ, 2016) |
| " We enrolled 141 patients and evaluated the efficacy and safety between a fixed dose of olmesartan/amlodipine (OA) and a double dose of amlodipine (DA) for treating mild to moderate hypertension after amlodipine monotherapy failure." | 9.17 | Efficacy and tolerability between an olmesartan/amlodipine fixed-dose combination and an amlodipine double dose in mild to moderate hypertension. ( Hou, CJ; Hsia, CH; Lai, WT; Lin, TH; Pan, JP; Tsai, CD; Tsai, JP, 2013) |
| "In this population of healthy subjects and patients with hypertension, segmental bioimpedance was comparable to water displacement and ankle circumference and outperformed clinical assessment of pitting for the detection of ankle edema, supporting the use of segmental bioimpedance as a drug-development tool to objectively quantify amlodipine-induced pedal edema." | 9.16 | Segmental bioimpedance for measuring amlodipine-induced pedal edema: a placebo-controlled study. ( Alon, A; Beals, CR; Bolognese, JA; Heymsfield, SB; Lasseter, KC; Manekas, D; Mixson, LA; Noonan, GP; Nunes, I; Schoeller, DA, 2012) |
| "This exploratory study compared the amount of pedal edema experienced by female Korean patients with mild to moderate hypertension when receiving S(-)-amlodipine nicotinate compared with amlodipine besylate." | 9.16 | Quantification of pedal edema during treatment with S(-)-amlodipine nicotinate versus amlodipine besylate in female Korean patients with mild to moderate hypertension: a 12-week, multicenter, randomized, double-blind, active-controlled, phase IV clinical ( Choi, DJ; Kang, HJ; Lee, HY; Oh, BH; Oh, GC; Zo, JH, 2012) |
| "The objective of this research was to evaluate the effect of telmisartan addition to amlodipine, on peripheral edema in hypertensive patients." | 9.15 | Effect of telmisartan addition to amlodipine on ankle edema development in treating hypertensive patients. ( Derosa, G; Fogari, R; Lazzari, P; Maffioli, P; Mugellini, A; Zoppi, A, 2011) |
| "After 4-week placebo, 120 outpatients with grade 1 - 2 hypertension were randomized to amlodipine 10 mg or aliskiren 300 mg or their combination for 8 weeks in three crossover periods." | 9.15 | Effect of aliskiren addition to amlodipine on ankle edema in hypertensive patients: a three-way crossover study. ( Derosa, G; Fogari, R; Lazzari, P; Maffioli, P; Monti, C; Mugellini, A; Zoppi, A, 2011) |
| "The objective of this Phase III double-blind parallel-group controlled study was to examine the superiority of amlodipine 10 mg once daily (the amlodipine 10 mg group) to amlodipine 5 mg once daily (the amlodipine 5 mg group) in 305 Japanese outpatients with essential hypertension whose systolic blood pressure (SBP) had not reached the therapeutic target levels (<130-140/80-90 mm Hg) when treated with amlodipine 5 mg once daily." | 9.14 | The Phase III, double-blind, parallel-group controlled study of amlodipine 10 mg once daily in Japanese patients with essential hypertension who insufficiently responded to amlodipine 5 mg once daily. ( Buch, J; Fujiwara, T; Hatsuzawa, J; Ii, Y; Kimura, N; Murakami, M; Murase, H; Saruta, T; Tsuchihashi, T; Watanabe, T, 2009) |
| "To demonstrate the benefit of the combination amlodipine/valsartan 5/160 mg over amlodipine 10 mg, in producing a lower incidence of peripheral oedema for a comparable mean sitting systolic blood pressure (MSSBP) reduction." | 9.14 | The combination of amlodipine/valsartan 5/160 mg produces less peripheral oedema than amlodipine 10 mg in hypertensive patients not adequately controlled with amlodipine 5 mg. ( Akpinar, E; Brunel, P; Calvo, C; Keeling, L; Salvetti, A; Schrader, J; Weisskopf, M, 2009) |
| "To evaluate the efficacy and tolerability of the fixed combination: amlodipine + enalapril, when compared to amlodipine in the normalization of the diastolic arterial pressure (DAP) (<85 mmHg), in pts with CAD and systemic arterial hypertension (SAH)." | 9.14 | Combination of amlodipine and enalapril in hypertensive patients with coronary disease. ( Armagnajian, D; César, LA; Ferreira, JF; Gomes, EP; Mansur, Ade P; Moretti, MA; Nogueira, PR; Ramires, JA; Rienzo, M; Saraiva, JF, 2009) |
| "The objective of this study was to compare the effect on ankle edema of adding valsartan (V) or olmesartan (O) to amlodipine (A) in the treatment of hypertension." | 9.14 | Effect of valsartan or olmesartan addition to amlodipine on ankle edema in hypertensive patients. ( Corradi, L; Derosa, G; Fogari, R; Malamani, G; Mugellini, A; Preti, P; Zoppi, A, 2010) |
| "This multicentre, double-blind, trial in subjects with severe hypertension compared the efficacy and tolerability of two parallel drug regimens: A/B (amlodipine/benazepril: 5/20 or 10/40 mg daily, if necessary) with A (amlodipine: 5 or 10 mg daily, if necessary)." | 9.14 | Comparative efficacy and safety of amlodipine/benazepril combination therapy and amlodipine monotherapy in severe hypertension. ( Hall, D; Hilkert, RJ; Izzo, JL; Purkayastha, D, 2010) |
| "In this population of patients with essential hypertension, the amlodipine/ramipril FDC was associated with significantly reduced ambulatory and office-measured BP compared with amlodipine monotherapy, with the exception of office DBP." | 9.13 | An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study. ( Amodeo, C; Filho, BL; Gomes, MA; Kohlmann, O; Mion, D; Miranda, RD; Rocha, JC; Saraiva, JF, 2008) |
| "The aim of this study was to assess the effect of valsartan addition to amlodipine on ankle foot volume (AFV) and pretibial subcutaneous tissue pressure (PSTP), two objective measures of ankle oedema." | 9.12 | Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. ( Derosa, G; Fogari, E; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Rinaldi, A; Zoppi, A, 2007) |
| "5 mg was compared with that of amlodipine, in a multicentre, double-blind, randomised, parallel-group study in patients with mild-to-moderate essential hypertension inadequately controlled by monotherapy." | 9.12 | Efficacy and tolerability of candesartan cilexetil/hydrochlorothiazide and amlodipine in patients with poorly controlled mild-to-moderate essential hypertension. ( Derosa, G; Fogari, R; Mugellini, A, 2007) |
| "The antihypertensive efficacy of nebivolol and amlodipine and their tolerability were compared in a multicentre, randomized, active-controlled, double-blind parallel-group trial in elderly patients with mild to moderate essential arterial hypertension." | 9.10 | Nebivolol vs amlodipine as first-line treatment of essential arterial hypertension in the elderly. ( Gil-Extremera, B; Maldonato, A; Mazza, A; Pessina, AC; Toutouzas, T, 2002) |
| "To compare the effect of amlodipine, a prototype dihydropyridine calcium-channel blocker with lercanidipine, a newer dihydropyridine compound with lipophilic properties, on dependent oedema generation and interference with skin blood flow vasomotion in hypertensive patients." | 9.10 | Heterogeneous effect of calcium antagonists on leg oedema: a comparison of amlodipine versus lercanidipine in hypertensive patients. ( Balbarini, A; Dell'Omo, G; Mariani, M; Menegato, A; Nuti, M; Pedrinelli, R, 2003) |
| "In postmenopausal females with mild to moderate hypertension the oedema formation of Lercanidipine was significantly less than that of Amlodipine, despite no significant differences in the antihypertensive effect." | 9.10 | Quantification of leg oedema in postmenopausal hypertensive patients treated with lercanidipine or amlodipine. ( Helberg, S; Istad, H; Lund-Johansen, P; Madsbu, S; Risberg, K; Rønnevik, PK; Stranden, E; Wessel-Aas, T, 2003) |
| "The aim of this study was to evaluate the effect of benazepril addition to amlodipine antihypertensive treatment on ankle-foot volume (AFV) and pretibial subcutaneous tissue pressure (PSTP), two objective measures of ankle oedema." | 9.10 | Effect of benazepril addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. ( Fogari, R; Malamani, GD; Mugellini, A; Preti, P; Rinaldi, A; Vanasia, A; Zoppi, A, 2003) |
| "All studies suggesting a lower incidence of edema on lacidipine than on amlodipine are based on subjective scoring." | 9.09 | Ankle edema formation during treatment with the calcium channel blockers lacidipine and amlodipine: a single-centre study. ( Andrésdóttir, MB; Huysmans, FT; Valk, IM; van de Bosch, WJ; van Hamersvelt, HW; van Helden, MJ, 2000) |
| "The comparative antihypertensive efficacy and tolerability of the angiotensin II receptor blocker candesartan cilexetil and the calcium channel blocker amlodipine were evaluated in an 8-week, multicenter, double-blind, randomized, parallel-group, forced-titration study in 251 adult patients (45% women, 16% black) with mild hypertension (stage 1)." | 9.09 | Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. Comparison of Candesartan and Amlodipine for Safety, Tolerability and Efficacy (CASTLE) Study Investigators. ( Chrysant, SG; Harris, SM; Kloner, RA; Leidy, NK; Michelson, EL; Pool, JL; Prasad, R; Weinberger, M; Zyczynski, TM, 2001) |
| " To evaluate the dose-response relation between this pharmacological interference and dependent edema, a frequent side effect of CCBs during antihypertensive treatment, skin blood flow (laser Doppler flowmetry) at the dorsum of the foot, both supine and with the limb passively placed 50 cm below the heart level, and leg weight (Archimedes principle) were measured at baseline, during increasing doses of the dihydropyridine amlodipine (5 and 10 mg UID each for 2 weeks), and after drug withdrawal in 10 hypertensive men." | 9.09 | Amlodipine, enalapril, and dependent leg edema in essential hypertension. ( Dell'Omo, G; Mariani, M; Melillo, E; Pedrinelli, R, 2000) |
| "One hundred sixty-eight adult outpatients with mild to moderate hypertension were randomly allocated in double-blind fashion and equal number to receive 80 mg valsartan or 5 mg amlodipine for 12 weeks." | 9.08 | Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine. ( Bodin, F; Cardoni, O; Corea, L; Fogari, R; Innocenti, P; Meilenbrock, S; Porcellati, C; Provvidenza, M; Sullivan, J, 1996) |
| "The present study aimed to assess the efficacy and tolerance of amlodipine (Norvasc-Pfizer) in the treatment of 152 patients with mild and moderate essential hypertension." | 9.08 | -Efficacy and safety of using amlodipine in treatment of mild and moderate essential hypertension-. ( Kokot, F; Kokot, M; Raszewska, J; Rychlik, G; Witkowicz, J, 1995) |
| "5-10 mg) once daily was compared with atenolol (50-100 mg) once daily in patients with mild-to-moderate essential hypertension in a randomized, double-blind, parallel, placebo-controlled study." | 9.07 | Amlodipine versus atenolol in essential hypertension. ( Brobyn, R; Brown, RD; Frishman, WH; Johnson, BF; Reeves, RL; Wombolt, DG, 1994) |
| "Use of amlodipine for treatment of arterial hypertension and stable coronary artery disease (CAD) is sometimes limited by occurrence of peripheral edema and headache." | 9.01 | Peripheral edema and headache associated with amlodipine treatment: a meta-analysis of randomized, placebo-controlled trials. ( Böhm, M; Mahfoud, F; Messerli, FH; Scholz, SS; Vukadinović, D; Weber, MA; Williams, B, 2019) |
| " Hypertensive Patients who were on amlodipine for at least 6 months and presented with pedal edema were enrolled for the study." | 8.02 | Cilnidipine for Amlodipine Induced Pedal Edema and its Anti-hypertensive Effect in a Tertiary Care Teaching Hospital of Western Nepal. ( Kafle, RC; Maskey, A; Sapkota, S, 2021) |
| "In this case report, we describe a rare case of amlodipine induced massive ascites in a 30-year-old male with renal transplantation." | 7.96 | Amlodipine Induced Massive Ascites, a Rare Clinical Case. ( Arasan, SN; Cevher, SK; Dede, F; Yenigun, EC, 2020) |
| "This prospective, open-label, postmarketing surveillance study enrolled adults with arterial hypertension (systolic BP >140 mmHg and/or diastolic BP >90 mmHg) who were prescribed antihypertensive therapy with single-pill combination amlodipine/valsartan 5/80, 5/160, or 10/160 mg once daily." | 7.78 | Amlodipine/valsartan single-pill combination: a prospective, observational evaluation of the real-life safety and effectiveness in the routine treatment of hypertension. ( Dongre, N; Karpov, Y; Sastravaha, K; Vigdorchik, A, 2012) |
| "To report a case of bilateral upper extremity edema associated with amlodipine use in a child." | 7.74 | Amlodipine-induced bilateral upper extremity edema. ( Ganeshalingham, A; Wong, W, 2007) |
| "To report a case of anasarca edema associated with amlodipine use." | 7.73 | Anasarca edema with amlodipine treatment. ( Arioğul, S; Cankurtaran, M; Halil, M; Sener, D; Yavuz, BB, 2005) |
| "0001), and a lower incidence of pedal edema and adverse events compared with amlodipine." | 6.80 | Efficacy and safety of perindopril arginine + amlodipine in hypertension. ( Bakris, GL; Elliott, WJ; Feldstein, JD; Whitmore, J, 2015) |
| " Both treatment groups had similar adverse event rates (35." | 6.76 | Comparative efficacy and safety of combination aliskiren/amlodipine and amlodipine monotherapy in African Americans with stage 2 hypertension. ( Black, HR; Hilkert, R; Israel, M; Izzo, J; Lee, J; Purkayastha, D; Sridharan, K; Weinberger, MH, 2011) |
| " Blood pressure measurements were taken at the end of the dosing interval to assess the antihypertensive efficacy of the two drugs." | 6.67 | At equipotent doses, isradipine is better tolerated than amlodipine in patients with mild-to-moderate hypertension: a double-blind, randomized, parallel-group study. ( De Keyser, P; Deblander, A; Hermans, L; Lesaffre, E; Scheys, I; Westelinck, KJ, 1994) |
| " Most adverse events were mild or moderate and the investigators' overall evaluation of tolerability was excellent or good for 91% of patients." | 6.67 | A study of the efficacy and safety of amlodipine for the treatment of hypertension in general practice. ( Varrone, J, 1991) |
| " A systematic review of the literature revealed its most common adverse effects as: peripheral edema (depending on the dose of amlodipine, but attenuated by perindopril), cough, dizziness and hypotension." | 6.58 | Perindopril arginine and amlodipine besylate for hypertension: a safety evaluation. ( Bistrika, EA; Elliott, WJ, 2018) |
| "Pedal oedema is a well-known adverse effect of amlodipine, but significantly less frequent if only half of the maximum recommended dosage is used." | 5.41 | ( Christensen, B; Helgestad, OK; Henriksen, JN; Oxlund, CS; Skovbjerg, BK, 2023) |
| "Amlodipine therapy was discontinued and oedema diminished markedly within 72 hours." | 5.39 | Generalised peripheral oedema associated with amlodipine therapy in two dogs. ( Creevy, KE; Ellis, AE; Scuderi, MA, 2013) |
| "Although hypertension is common (30% of adults in the USA), its control to recommended blood pressure levels of under 140/90 mmHg remains low, at 36." | 5.35 | Amlodipine besylate/olmesartan medoximil fixed combination for the treatment of hypertension. ( Chrysant, SG, 2009) |
| "Chlorthalidone is a very effective antihypertensive drug, but it has not been studied prospectively in kidney transplant recipients with hypertension." | 5.24 | Chlorthalidone Versus Amlodipine for Hypertension in Kidney Transplant Recipients Treated With Tacrolimus: A Randomized Crossover Trial. ( Hesselink, DA; Hoorn, EJ; Moes, AD; van den Meiracker, AH; Zietse, R, 2017) |
| "In hypertensive patients not controlled on prior BB and ACEI/ARB therapy, addition of (S)-amlodipine besylate at half the dose of conventional amlodipine provides better tolerability with reduced incidence of peripheral edema, and equal antihypertensive efficacy compared to amlodipine given at usual doses." | 5.22 | Leg edema with (S)-amlodipine vs conventional amlodipine given in triple therapy for hypertension: a randomized double blind controlled clinical trial. ( Ekanayaka, RA; Galappatthy, GK; Galappatthy, P; Sabeer, MI; Waniganayake, YC; Wijethunga, TJ, 2016) |
| " We enrolled 141 patients and evaluated the efficacy and safety between a fixed dose of olmesartan/amlodipine (OA) and a double dose of amlodipine (DA) for treating mild to moderate hypertension after amlodipine monotherapy failure." | 5.17 | Efficacy and tolerability between an olmesartan/amlodipine fixed-dose combination and an amlodipine double dose in mild to moderate hypertension. ( Hou, CJ; Hsia, CH; Lai, WT; Lin, TH; Pan, JP; Tsai, CD; Tsai, JP, 2013) |
| "This exploratory study compared the amount of pedal edema experienced by female Korean patients with mild to moderate hypertension when receiving S(-)-amlodipine nicotinate compared with amlodipine besylate." | 5.16 | Quantification of pedal edema during treatment with S(-)-amlodipine nicotinate versus amlodipine besylate in female Korean patients with mild to moderate hypertension: a 12-week, multicenter, randomized, double-blind, active-controlled, phase IV clinical ( Choi, DJ; Kang, HJ; Lee, HY; Oh, BH; Oh, GC; Zo, JH, 2012) |
| "In this population of healthy subjects and patients with hypertension, segmental bioimpedance was comparable to water displacement and ankle circumference and outperformed clinical assessment of pitting for the detection of ankle edema, supporting the use of segmental bioimpedance as a drug-development tool to objectively quantify amlodipine-induced pedal edema." | 5.16 | Segmental bioimpedance for measuring amlodipine-induced pedal edema: a placebo-controlled study. ( Alon, A; Beals, CR; Bolognese, JA; Heymsfield, SB; Lasseter, KC; Manekas, D; Mixson, LA; Noonan, GP; Nunes, I; Schoeller, DA, 2012) |
| "After 4-week placebo, 120 outpatients with grade 1 - 2 hypertension were randomized to amlodipine 10 mg or aliskiren 300 mg or their combination for 8 weeks in three crossover periods." | 5.15 | Effect of aliskiren addition to amlodipine on ankle edema in hypertensive patients: a three-way crossover study. ( Derosa, G; Fogari, R; Lazzari, P; Maffioli, P; Monti, C; Mugellini, A; Zoppi, A, 2011) |
| "The objective of this research was to evaluate the effect of telmisartan addition to amlodipine, on peripheral edema in hypertensive patients." | 5.15 | Effect of telmisartan addition to amlodipine on ankle edema development in treating hypertensive patients. ( Derosa, G; Fogari, R; Lazzari, P; Maffioli, P; Mugellini, A; Zoppi, A, 2011) |
| "The objective of this study was to compare the effect on ankle edema of adding valsartan (V) or olmesartan (O) to amlodipine (A) in the treatment of hypertension." | 5.14 | Effect of valsartan or olmesartan addition to amlodipine on ankle edema in hypertensive patients. ( Corradi, L; Derosa, G; Fogari, R; Malamani, G; Mugellini, A; Preti, P; Zoppi, A, 2010) |
| "This multicentre, double-blind, trial in subjects with severe hypertension compared the efficacy and tolerability of two parallel drug regimens: A/B (amlodipine/benazepril: 5/20 or 10/40 mg daily, if necessary) with A (amlodipine: 5 or 10 mg daily, if necessary)." | 5.14 | Comparative efficacy and safety of amlodipine/benazepril combination therapy and amlodipine monotherapy in severe hypertension. ( Hall, D; Hilkert, RJ; Izzo, JL; Purkayastha, D, 2010) |
| "5%) and none of lercanidipine group developed edema; p = 0." | 5.14 | Comparison of changes of body water measured by using bioelectrical impedance analysis between lercanidipine and amlodipine therapy in hypertensive outpatients. ( Sansanayudh, N; Veerayuthvilai, S; Wongwiwatthananukit, S, 2010) |
| "To evaluate the efficacy and tolerability of the fixed combination: amlodipine + enalapril, when compared to amlodipine in the normalization of the diastolic arterial pressure (DAP) (<85 mmHg), in pts with CAD and systemic arterial hypertension (SAH)." | 5.14 | Combination of amlodipine and enalapril in hypertensive patients with coronary disease. ( Armagnajian, D; César, LA; Ferreira, JF; Gomes, EP; Mansur, Ade P; Moretti, MA; Nogueira, PR; Ramires, JA; Rienzo, M; Saraiva, JF, 2009) |
| "To demonstrate the benefit of the combination amlodipine/valsartan 5/160 mg over amlodipine 10 mg, in producing a lower incidence of peripheral oedema for a comparable mean sitting systolic blood pressure (MSSBP) reduction." | 5.14 | The combination of amlodipine/valsartan 5/160 mg produces less peripheral oedema than amlodipine 10 mg in hypertensive patients not adequately controlled with amlodipine 5 mg. ( Akpinar, E; Brunel, P; Calvo, C; Keeling, L; Salvetti, A; Schrader, J; Weisskopf, M, 2009) |
| "The objective of this Phase III double-blind parallel-group controlled study was to examine the superiority of amlodipine 10 mg once daily (the amlodipine 10 mg group) to amlodipine 5 mg once daily (the amlodipine 5 mg group) in 305 Japanese outpatients with essential hypertension whose systolic blood pressure (SBP) had not reached the therapeutic target levels (<130-140/80-90 mm Hg) when treated with amlodipine 5 mg once daily." | 5.14 | The Phase III, double-blind, parallel-group controlled study of amlodipine 10 mg once daily in Japanese patients with essential hypertension who insufficiently responded to amlodipine 5 mg once daily. ( Buch, J; Fujiwara, T; Hatsuzawa, J; Ii, Y; Kimura, N; Murakami, M; Murase, H; Saruta, T; Tsuchihashi, T; Watanabe, T, 2009) |
| "In this population of patients with essential hypertension, the amlodipine/ramipril FDC was associated with significantly reduced ambulatory and office-measured BP compared with amlodipine monotherapy, with the exception of office DBP." | 5.13 | An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study. ( Amodeo, C; Filho, BL; Gomes, MA; Kohlmann, O; Mion, D; Miranda, RD; Rocha, JC; Saraiva, JF, 2008) |
| "The aim of this study was to assess the effect of valsartan addition to amlodipine on ankle foot volume (AFV) and pretibial subcutaneous tissue pressure (PSTP), two objective measures of ankle oedema." | 5.12 | Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. ( Derosa, G; Fogari, E; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Rinaldi, A; Zoppi, A, 2007) |
| "Two studies were conducted to compare the efficacy of various combinations of amlodipine and valsartan administered once daily with their individual components and placebo in patients with mild to moderate essential hypertension (mean sitting diastolic blood pressure [MSDBP] >/=95 and < 110 mm Hg)." | 5.12 | Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hyperten ( Glazer, R; Jin, J; Philipp, T; Pospiech, R; Schneider, H; Smith, TR; Wernsing, M; Yen, J, 2007) |
| "5 mg was compared with that of amlodipine, in a multicentre, double-blind, randomised, parallel-group study in patients with mild-to-moderate essential hypertension inadequately controlled by monotherapy." | 5.12 | Efficacy and tolerability of candesartan cilexetil/hydrochlorothiazide and amlodipine in patients with poorly controlled mild-to-moderate essential hypertension. ( Derosa, G; Fogari, R; Mugellini, A, 2007) |
| "The aim of this study was to evaluate the efficacy and tolerability of a new fixed-dose combination (FDC) of telmisartan 40 mg + amlodipine 5 mg (T+A) compared with amlodipine 5-mg monotherapy (A) in adult Indian patients with stage II hypertension." | 5.12 | Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stag ( Bagchi, A; Baliga, VP; Bollmall, C; Kinagi, SB; Sharma, A; Sharma, YK, 2007) |
| "This multicenter, double-blind, 12-week study randomized 364 patients with stage 2 hypertension to fixed-dose combination therapy with amlodipine besylate/benazepril HCl (5/20 mg/d titrated to 10/20 mg/d) or amlodipine besylate monotherapy (5 mg/d titrated to 10 mg/d)." | 5.11 | Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension. ( Baron, M; Jamerson, KA; Jean-Louis, L; Nwose, O; Purkayastha, D; Schofield, L, 2004) |
| " We investigated the effects on 24-h ambulatory blood pressure (ABP) of the angiotensin-receptor blocker, valsartan, in combination with hydrochlorothiazide (HCTZ), compared with the calcium-channel blocker amlodipine in a Brazilian population in a multicentre, double-blind, double-dummy, parallel group, controlled study in 373 patients with essential hypertension." | 5.10 | Efficacy and tolerability of the combination valsartan/hydrochlorothiazide compared with amlodipine in a mild-to-moderately hypertensive Brazilian population. ( Franco, RJ; Goldflus, S; McQuitty, M; Oigman, W, 2003) |
| "The aim of this study was to evaluate the effect of benazepril addition to amlodipine antihypertensive treatment on ankle-foot volume (AFV) and pretibial subcutaneous tissue pressure (PSTP), two objective measures of ankle oedema." | 5.10 | Effect of benazepril addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. ( Fogari, R; Malamani, GD; Mugellini, A; Preti, P; Rinaldi, A; Vanasia, A; Zoppi, A, 2003) |
| "In postmenopausal females with mild to moderate hypertension the oedema formation of Lercanidipine was significantly less than that of Amlodipine, despite no significant differences in the antihypertensive effect." | 5.10 | Quantification of leg oedema in postmenopausal hypertensive patients treated with lercanidipine or amlodipine. ( Helberg, S; Istad, H; Lund-Johansen, P; Madsbu, S; Risberg, K; Rønnevik, PK; Stranden, E; Wessel-Aas, T, 2003) |
| "The antihypertensive efficacy of nebivolol and amlodipine and their tolerability were compared in a multicentre, randomized, active-controlled, double-blind parallel-group trial in elderly patients with mild to moderate essential arterial hypertension." | 5.10 | Nebivolol vs amlodipine as first-line treatment of essential arterial hypertension in the elderly. ( Gil-Extremera, B; Maldonato, A; Mazza, A; Pessina, AC; Toutouzas, T, 2002) |
| "To compare the effect of amlodipine, a prototype dihydropyridine calcium-channel blocker with lercanidipine, a newer dihydropyridine compound with lipophilic properties, on dependent oedema generation and interference with skin blood flow vasomotion in hypertensive patients." | 5.10 | Heterogeneous effect of calcium antagonists on leg oedema: a comparison of amlodipine versus lercanidipine in hypertensive patients. ( Balbarini, A; Dell'Omo, G; Mariani, M; Menegato, A; Nuti, M; Pedrinelli, R, 2003) |
| "Hypertensive patients currently taking amlodipine were selected based on one of two criteria: inadequate blood pressure (BP) control on amlodipine (diastolic BP [DBP] > or = 90 mm Hg; group 1), or inability to tolerate amlodipine (DBP < or = 90 mm Hg, but with edema; group 2)." | 5.10 | Combination therapy of amlodipine/benazepril versus monotherapy of amlodipine in a practice-based setting. ( Messerli, FH; Neutel, JM; Weir, MR, 2002) |
| " To evaluate the dose-response relation between this pharmacological interference and dependent edema, a frequent side effect of CCBs during antihypertensive treatment, skin blood flow (laser Doppler flowmetry) at the dorsum of the foot, both supine and with the limb passively placed 50 cm below the heart level, and leg weight (Archimedes principle) were measured at baseline, during increasing doses of the dihydropyridine amlodipine (5 and 10 mg UID each for 2 weeks), and after drug withdrawal in 10 hypertensive men." | 5.09 | Amlodipine, enalapril, and dependent leg edema in essential hypertension. ( Dell'Omo, G; Mariani, M; Melillo, E; Pedrinelli, R, 2000) |
| "The comparative antihypertensive efficacy and tolerability of the angiotensin II receptor blocker candesartan cilexetil and the calcium channel blocker amlodipine were evaluated in an 8-week, multicenter, double-blind, randomized, parallel-group, forced-titration study in 251 adult patients (45% women, 16% black) with mild hypertension (stage 1)." | 5.09 | Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. Comparison of Candesartan and Amlodipine for Safety, Tolerability and Efficacy (CASTLE) Study Investigators. ( Chrysant, SG; Harris, SM; Kloner, RA; Leidy, NK; Michelson, EL; Pool, JL; Prasad, R; Weinberger, M; Zyczynski, TM, 2001) |
| "All studies suggesting a lower incidence of edema on lacidipine than on amlodipine are based on subjective scoring." | 5.09 | Ankle edema formation during treatment with the calcium channel blockers lacidipine and amlodipine: a single-centre study. ( Andrésdóttir, MB; Huysmans, FT; Valk, IM; van de Bosch, WJ; van Hamersvelt, HW; van Helden, MJ, 2000) |
| "This community-based study assessed whether there were age, sex, or racial differences in response to amlodipine 5 to 10 mg once daily in patients with mild to moderate essential hypertension." | 5.08 | Sex- and age-related antihypertensive effects of amlodipine. The Amlodipine Cardiovascular Community Trial Study Group. ( DiBona, GF; Gaffney, M; Kloner, RA; Sowers, JR; Wein, M, 1996) |
| "The present study aimed to assess the efficacy and tolerance of amlodipine (Norvasc-Pfizer) in the treatment of 152 patients with mild and moderate essential hypertension." | 5.08 | -Efficacy and safety of using amlodipine in treatment of mild and moderate essential hypertension-. ( Kokot, F; Kokot, M; Raszewska, J; Rychlik, G; Witkowicz, J, 1995) |
| "One hundred sixty-eight adult outpatients with mild to moderate hypertension were randomly allocated in double-blind fashion and equal number to receive 80 mg valsartan or 5 mg amlodipine for 12 weeks." | 5.08 | Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine. ( Bodin, F; Cardoni, O; Corea, L; Fogari, R; Innocenti, P; Meilenbrock, S; Porcellati, C; Provvidenza, M; Sullivan, J, 1996) |
| "5-10 mg) once daily was compared with atenolol (50-100 mg) once daily in patients with mild-to-moderate essential hypertension in a randomized, double-blind, parallel, placebo-controlled study." | 5.07 | Amlodipine versus atenolol in essential hypertension. ( Brobyn, R; Brown, RD; Frishman, WH; Johnson, BF; Reeves, RL; Wombolt, DG, 1994) |
| "In a multicentre crossover study of 97 patients with mild hypertension, the incidence and severity of adverse effects were observed during the first 14 days of treatment with amlodipine, nifedipine retard or placebo." | 5.07 | Early side-effects of antihypertensive therapy: comparison of amlodipine and nifedipine retard. ( Bremner, AD; Fell, PJ; Hosie, J; James, IG; Saul, PA; Taylor, SH, 1993) |
| "Use of amlodipine for treatment of arterial hypertension and stable coronary artery disease (CAD) is sometimes limited by occurrence of peripheral edema and headache." | 5.01 | Peripheral edema and headache associated with amlodipine treatment: a meta-analysis of randomized, placebo-controlled trials. ( Böhm, M; Mahfoud, F; Messerli, FH; Scholz, SS; Vukadinović, D; Weber, MA; Williams, B, 2019) |
| " Hypertensive Patients who were on amlodipine for at least 6 months and presented with pedal edema were enrolled for the study." | 4.02 | Cilnidipine for Amlodipine Induced Pedal Edema and its Anti-hypertensive Effect in a Tertiary Care Teaching Hospital of Western Nepal. ( Kafle, RC; Maskey, A; Sapkota, S, 2021) |
| "In this case report, we describe a rare case of amlodipine induced massive ascites in a 30-year-old male with renal transplantation." | 3.96 | Amlodipine Induced Massive Ascites, a Rare Clinical Case. ( Arasan, SN; Cevher, SK; Dede, F; Yenigun, EC, 2020) |
| "Hereby, we report four paediatric cases with amlodipine-related generalised oedema." | 3.85 | Amlodipine: The double edged sword. ( Al-Nabhani, D; El-Naggari, M; Rabah, F, 2017) |
| "the Indonesian subset of the EXCITE (clinical EXperience of amlodIpine and valsarTan in hypErtension) study, which was a multinational, prospective, observational, open study in hypertensive patients treated with Aml/Val SPC for 26 weeks." | 3.81 | Clinical Effectiveness, Safety and Tolerability of Amlodipine/Valsartan in Hypertensive Patients: the Indonesian Subset of the EXCITE Study. ( Abdillah, A; Kalim, H; Setiawati, A, 2015) |
| "This prospective, open-label, postmarketing surveillance study enrolled adults with arterial hypertension (systolic BP >140 mmHg and/or diastolic BP >90 mmHg) who were prescribed antihypertensive therapy with single-pill combination amlodipine/valsartan 5/80, 5/160, or 10/160 mg once daily." | 3.78 | Amlodipine/valsartan single-pill combination: a prospective, observational evaluation of the real-life safety and effectiveness in the routine treatment of hypertension. ( Dongre, N; Karpov, Y; Sastravaha, K; Vigdorchik, A, 2012) |
| "To report a case of conjunctival chemosis and bipedal edema associated with amlodipine besylate antihypertensive medication." | 3.77 | Chronic conjunctival chemosis from amlodipine besylate (Norvasc). ( Bianciotto, C; Say, EA; Shields, CL; Shields, JA, 2011) |
| "Lower leg edema is a common side effect of amlodipine therapy, but is often unrecognized as a contributor to stasis dermatitis." | 3.75 | Stasis dermatitis as a complication of amlodipine therapy. ( Gosnell, AL; Nedorost, ST, 2009) |
| "To report a case of bilateral upper extremity edema associated with amlodipine use in a child." | 3.74 | Amlodipine-induced bilateral upper extremity edema. ( Ganeshalingham, A; Wong, W, 2007) |
| "To report a case of anasarca edema associated with amlodipine use." | 3.73 | Anasarca edema with amlodipine treatment. ( Arioğul, S; Cankurtaran, M; Halil, M; Sener, D; Yavuz, BB, 2005) |
| "0001), and a lower incidence of pedal edema and adverse events compared with amlodipine." | 2.80 | Efficacy and safety of perindopril arginine + amlodipine in hypertension. ( Bakris, GL; Elliott, WJ; Feldstein, JD; Whitmore, J, 2015) |
| " Both treatment groups had similar adverse event rates (35." | 2.76 | Comparative efficacy and safety of combination aliskiren/amlodipine and amlodipine monotherapy in African Americans with stage 2 hypertension. ( Black, HR; Hilkert, R; Israel, M; Izzo, J; Lee, J; Purkayastha, D; Sridharan, K; Weinberger, MH, 2011) |
| "The primary aim of this double-blind, parallel group trial was to compare incidence of newly occurring vasodilatory adverse events in elderly patients treated with recommended once-daily doses of felodipine extended release (ER) or amlodipine." | 2.69 | Improved tolerability of felodipine compared with amlodipine in elderly hypertensives: a randomised, double-blind study in 535 patients, focusing on vasodilatory adverse events. The International Study Group. ( Aldons, PM; Burgess, ED; Girerd, X; Morgan, TO; Rehn, L; Schaefer, RM; Singh, GP; Tilvis, R, 1998) |
| " Most adverse events were mild or moderate and the investigators' overall evaluation of tolerability was excellent or good for 91% of patients." | 2.67 | A study of the efficacy and safety of amlodipine for the treatment of hypertension in general practice. ( Varrone, J, 1991) |
| " Blood pressure measurements were taken at the end of the dosing interval to assess the antihypertensive efficacy of the two drugs." | 2.67 | At equipotent doses, isradipine is better tolerated than amlodipine in patients with mild-to-moderate hypertension: a double-blind, randomized, parallel-group study. ( De Keyser, P; Deblander, A; Hermans, L; Lesaffre, E; Scheys, I; Westelinck, KJ, 1994) |
| "Amlodipine treatment was associated with a slightly higher incidence of side effects compared with placebo, but most of this difference was the result of edema, which was usually well tolerated." | 2.66 | The safety of amlodipine. ( Osterloh, I, 1989) |
| " A systematic review of the literature revealed its most common adverse effects as: peripheral edema (depending on the dose of amlodipine, but attenuated by perindopril), cough, dizziness and hypotension." | 2.58 | Perindopril arginine and amlodipine besylate for hypertension: a safety evaluation. ( Bistrika, EA; Elliott, WJ, 2018) |
| " Head-to-head randomized controlled trials (RCTs) of 12 months minimum duration reporting comparative efficacy (changes in systolic and diastolic blood pressure) and safety (total adverse events and ankle oedema), were included." | 2.47 | Efficacy and safety profiles of manidipine compared with amlodipine: a meta-analysis of head-to-head trials. ( Laurent, S; Richy, FF, 2011) |
| "CCB-induced oedema is caused by increased capillary hydrostatic pressure that results from preferential dilation of pre-capillary vessels." | 2.45 | Mitigation of calcium channel blocker-related oedema in hypertension by antagonists of the renin-angiotensin system. ( de la Sierra, A, 2009) |
| "Amlodipine therapy was discontinued and oedema diminished markedly within 72 hours." | 1.39 | Generalised peripheral oedema associated with amlodipine therapy in two dogs. ( Creevy, KE; Ellis, AE; Scuderi, MA, 2013) |
| "A 35-year-old woman with a history of breast cancer, treated 3 years ago with surgery, radiation, and chemotherapy presented with a rapid onset of severe Raynaud's phenomenon." | 1.36 | Paraneoplastic Raynaud's phenomenon in a breast cancer survivor. ( Allen, D; Mittoo, S; Robinson, D, 2010) |
| "Although hypertension is common (30% of adults in the USA), its control to recommended blood pressure levels of under 140/90 mmHg remains low, at 36." | 1.35 | Amlodipine besylate/olmesartan medoximil fixed combination for the treatment of hypertension. ( Chrysant, SG, 2009) |
| "Edema is a common symptom in elderly patients and we frequently observe drug-induced edema." | 1.31 | [A case of severe systemic edema in an elderly hypertensive patient with systemic lupus erythematodes during long-term treatment with anti-hypertensive drugs]. ( Higaki, J; Iegushi, K; Maekawa, Y; Moriguchi, A; Ogihara, T; Ohishi, M; Orita, H; Rakugi, H; Sugimoto, K, 2001) |
| "To compare the effects of chronic administration of two dihydropyridines, nifedipine and amlodipine, and the non-dihydropyridine Ca2+ antagonist mibefradil on fluid filtration of large arteries and extravasation of albumin in spontaneously hypertensive rats." | 1.30 | Different effects of calcium antagonists on fluid filtration of large arteries and albumin permeability in spontaneously hypertensive rats. ( Koen, R; Lacolley, P; Levy, BI; Poitevin, P, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (2.63) | 18.7374 |
| 1990's | 14 (18.42) | 18.2507 |
| 2000's | 30 (39.47) | 29.6817 |
| 2010's | 25 (32.89) | 24.3611 |
| 2020's | 5 (6.58) | 2.80 |
| Authors | Studies |
|---|---|
| Kafle, RC | 1 |
| Sapkota, S | 1 |
| Maskey, A | 1 |
| Skovbjerg, BK | 1 |
| Helgestad, OK | 1 |
| Oxlund, CS | 1 |
| Christensen, B | 1 |
| Henriksen, JN | 1 |
| Padhani, ZA | 1 |
| Gangwani, MK | 1 |
| Sadaf, A | 1 |
| Hasan, B | 1 |
| Colan, S | 1 |
| Alvi, N | 1 |
| Das, JK | 1 |
| Arasan, SN | 1 |
| Yenigun, EC | 1 |
| Cevher, SK | 1 |
| Dede, F | 1 |
| Aung, TKK | 1 |
| Chuah, TY | 1 |
| Chua, MWJ | 1 |
| Rabah, F | 1 |
| El-Naggari, M | 1 |
| Al-Nabhani, D | 1 |
| Elliott, WJ | 2 |
| Bistrika, EA | 1 |
| Jeon, SY | 1 |
| Lee, NR | 1 |
| Yim, CY | 1 |
| Vukadinović, D | 1 |
| Scholz, SS | 1 |
| Messerli, FH | 4 |
| Weber, MA | 1 |
| Williams, B | 1 |
| Böhm, M | 1 |
| Mahfoud, F | 1 |
| Lin, TH | 1 |
| Tsai, CD | 1 |
| Pan, JP | 1 |
| Hou, CJ | 1 |
| Hsia, CH | 1 |
| Tsai, JP | 1 |
| Lai, WT | 1 |
| Creevy, KE | 1 |
| Scuderi, MA | 1 |
| Ellis, AE | 1 |
| Whitmore, J | 1 |
| Feldstein, JD | 1 |
| Bakris, GL | 1 |
| Setiawati, A | 1 |
| Kalim, H | 1 |
| Abdillah, A | 1 |
| Hatalova, K | 1 |
| Pella, D | 1 |
| Sidlo, R | 1 |
| Hatala, R | 1 |
| Galappatthy, P | 1 |
| Waniganayake, YC | 1 |
| Sabeer, MI | 1 |
| Wijethunga, TJ | 1 |
| Galappatthy, GK | 1 |
| Ekanayaka, RA | 1 |
| Maneshi, A | 1 |
| Ravi, S | 1 |
| Salehi, MR | 1 |
| Hasannezhad, M | 1 |
| Khalili, H | 1 |
| Moes, AD | 1 |
| Hesselink, DA | 1 |
| van den Meiracker, AH | 1 |
| Zietse, R | 1 |
| Hoorn, EJ | 1 |
| Haugh, MJ | 1 |
| Miranda, RD | 1 |
| Mion, D | 1 |
| Rocha, JC | 1 |
| Kohlmann, O | 1 |
| Gomes, MA | 1 |
| Saraiva, JF | 2 |
| Amodeo, C | 1 |
| Filho, BL | 1 |
| de la Sierra, A | 1 |
| Fujiwara, T | 1 |
| Ii, Y | 1 |
| Hatsuzawa, J | 1 |
| Murase, H | 1 |
| Watanabe, T | 1 |
| Murakami, M | 1 |
| Kimura, N | 1 |
| Buch, J | 1 |
| Tsuchihashi, T | 1 |
| Saruta, T | 1 |
| Schrader, J | 1 |
| Salvetti, A | 1 |
| Calvo, C | 1 |
| Akpinar, E | 1 |
| Keeling, L | 1 |
| Weisskopf, M | 1 |
| Brunel, P | 1 |
| Gosnell, AL | 1 |
| Nedorost, ST | 1 |
| Rienzo, M | 1 |
| Nogueira, PR | 1 |
| Gomes, EP | 1 |
| Moretti, MA | 1 |
| Ferreira, JF | 1 |
| Armagnajian, D | 1 |
| Mansur, Ade P | 1 |
| Ramires, JA | 1 |
| César, LA | 1 |
| Allen, D | 1 |
| Robinson, D | 1 |
| Mittoo, S | 1 |
| Littlejohn, TW | 1 |
| Majul, CR | 1 |
| Olvera, R | 1 |
| Seeber, M | 1 |
| Kobe, M | 1 |
| Guthrie, R | 1 |
| Oigman, W | 2 |
| Chrysant, SG | 2 |
| Izzo, JL | 1 |
| Purkayastha, D | 3 |
| Hall, D | 1 |
| Hilkert, RJ | 1 |
| Fogari, R | 7 |
| Malamani, G | 1 |
| Corradi, L | 1 |
| Mugellini, A | 6 |
| Preti, P | 3 |
| Zoppi, A | 5 |
| Derosa, G | 5 |
| Richy, FF | 1 |
| Laurent, S | 1 |
| Say, EA | 1 |
| Shields, CL | 1 |
| Bianciotto, C | 1 |
| Shields, JA | 1 |
| Sansanayudh, N | 1 |
| Wongwiwatthananukit, S | 1 |
| Veerayuthvilai, S | 1 |
| Maffioli, P | 2 |
| Lazzari, P | 3 |
| Monti, C | 1 |
| Black, HR | 1 |
| Weinberger, MH | 1 |
| Lee, J | 1 |
| Sridharan, K | 1 |
| Israel, M | 1 |
| Hilkert, R | 1 |
| Izzo, J | 1 |
| Karpov, Y | 1 |
| Dongre, N | 1 |
| Vigdorchik, A | 1 |
| Sastravaha, K | 1 |
| Schoeller, DA | 1 |
| Alon, A | 1 |
| Manekas, D | 1 |
| Mixson, LA | 1 |
| Lasseter, KC | 1 |
| Noonan, GP | 1 |
| Bolognese, JA | 1 |
| Heymsfield, SB | 1 |
| Beals, CR | 1 |
| Nunes, I | 1 |
| Szabolcsi, O | 1 |
| Nagy-Toldi, A | 1 |
| Zeher, M | 1 |
| Végh, J | 1 |
| Oh, GC | 1 |
| Lee, HY | 1 |
| Kang, HJ | 1 |
| Zo, JH | 1 |
| Choi, DJ | 1 |
| Oh, BH | 1 |
| Mazza, A | 1 |
| Gil-Extremera, B | 1 |
| Maldonato, A | 1 |
| Toutouzas, T | 1 |
| Pessina, AC | 2 |
| von Vigier, RO | 1 |
| Fossali, E | 1 |
| Edefonti, A | 1 |
| Vogt, B | 1 |
| Bianchetti, MG | 1 |
| Leonetti, G | 1 |
| Magnani, B | 1 |
| Rappelli, A | 1 |
| Trimarco, B | 1 |
| Zanchetti, A | 1 |
| Grossman, E | 1 |
| Malamani, GD | 1 |
| Rinaldi, A | 2 |
| Vanasia, A | 1 |
| Lund-Johansen, P | 1 |
| Stranden, E | 1 |
| Helberg, S | 1 |
| Wessel-Aas, T | 1 |
| Risberg, K | 1 |
| Rønnevik, PK | 1 |
| Istad, H | 1 |
| Madsbu, S | 1 |
| Pedrinelli, R | 2 |
| Dell'Omo, G | 2 |
| Nuti, M | 1 |
| Menegato, A | 1 |
| Balbarini, A | 1 |
| Mariani, M | 2 |
| Franco, RJ | 1 |
| Goldflus, S | 1 |
| McQuitty, M | 1 |
| Jamerson, KA | 1 |
| Nwose, O | 1 |
| Jean-Louis, L | 1 |
| Schofield, L | 1 |
| Baron, M | 1 |
| Sener, D | 1 |
| Halil, M | 1 |
| Yavuz, BB | 1 |
| Cankurtaran, M | 1 |
| Arioğul, S | 1 |
| Fogari, E | 1 |
| Philipp, T | 1 |
| Smith, TR | 1 |
| Glazer, R | 1 |
| Wernsing, M | 1 |
| Yen, J | 1 |
| Jin, J | 1 |
| Schneider, H | 1 |
| Pospiech, R | 1 |
| Ganeshalingham, A | 1 |
| Wong, W | 1 |
| Sharma, A | 1 |
| Bagchi, A | 1 |
| Kinagi, SB | 1 |
| Sharma, YK | 1 |
| Baliga, VP | 1 |
| Bollmall, C | 1 |
| Hermans, L | 1 |
| Deblander, A | 1 |
| De Keyser, P | 1 |
| Scheys, I | 1 |
| Lesaffre, E | 1 |
| Westelinck, KJ | 1 |
| Chahine, RA | 2 |
| Feldman, RL | 2 |
| Giles, TD | 2 |
| Nicod, P | 2 |
| Raizner, AE | 2 |
| Weiss, RJ | 2 |
| Vanov, SK | 1 |
| Frishman, WH | 1 |
| Brobyn, R | 1 |
| Brown, RD | 1 |
| Johnson, BF | 1 |
| Reeves, RL | 1 |
| Wombolt, DG | 1 |
| Bremner, AD | 1 |
| Fell, PJ | 1 |
| Hosie, J | 1 |
| James, IG | 1 |
| Saul, PA | 1 |
| Taylor, SH | 1 |
| Kloner, RA | 2 |
| Sowers, JR | 1 |
| DiBona, GF | 1 |
| Gaffney, M | 1 |
| Wein, M | 1 |
| Kokot, F | 1 |
| Witkowicz, J | 1 |
| Kokot, M | 1 |
| Rychlik, G | 1 |
| Raszewska, J | 1 |
| Corea, L | 1 |
| Cardoni, O | 1 |
| Innocenti, P | 1 |
| Porcellati, C | 1 |
| Provvidenza, M | 1 |
| Meilenbrock, S | 1 |
| Sullivan, J | 1 |
| Bodin, F | 1 |
| Spratt, KA | 1 |
| Massie, BM | 1 |
| Lacourcière, Y | 1 |
| Viskoper, R | 1 |
| Woittiez, A | 1 |
| Kobrin, I | 1 |
| Lacolley, P | 1 |
| Poitevin, P | 1 |
| Koen, R | 1 |
| Levy, BI | 1 |
| Schaefer, RM | 1 |
| Aldons, PM | 1 |
| Burgess, ED | 1 |
| Tilvis, R | 1 |
| Girerd, X | 1 |
| Singh, GP | 1 |
| Rehn, L | 1 |
| Morgan, TO | 1 |
| Zambanini, A | 1 |
| Padley, S | 1 |
| Cox, A | 1 |
| Feher, M | 1 |
| Melillo, E | 1 |
| Weinberger, M | 1 |
| Pool, JL | 1 |
| Prasad, R | 1 |
| Harris, SM | 1 |
| Zyczynski, TM | 1 |
| Leidy, NK | 1 |
| Michelson, EL | 1 |
| Andrésdóttir, MB | 1 |
| van Hamersvelt, HW | 1 |
| van Helden, MJ | 1 |
| van de Bosch, WJ | 1 |
| Valk, IM | 1 |
| Huysmans, FT | 1 |
| Maekawa, Y | 1 |
| Sugimoto, K | 1 |
| Ohishi, M | 1 |
| Moriguchi, A | 1 |
| Rakugi, H | 1 |
| Iegushi, K | 1 |
| Orita, H | 1 |
| Higaki, J | 1 |
| Ogihara, T | 1 |
| Hall, R | 1 |
| Chong, C | 1 |
| Weir, MR | 1 |
| Neutel, JM | 1 |
| Varrone, J | 1 |
| Osterloh, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A 12 Weeks, Multi-center, Randomized, Open Label, Active Control, Phase IV Clinical Trial to Compare Evaluated Improvement of Edema Index, Safety and Efficacy of Amlodipine Versus S Amlodipine in Patients With Essential Hypertension[NCT04554303] | 80 participants (Anticipated) | Observational | 2020-10-28 | Recruiting | |||
| Thiazide Diuretics for Hypertension in Kidney Transplant Recipients Using Tacrolimus[NCT02644395] | Phase 3 | 49 participants (Actual) | Interventional | 2013-01-18 | Completed | ||
| Pilot Study to Assess Blockade of Calcium Channels and Sodium Chloride Cotransporters for Physiologic Abnormalities in Liver Transplant Associated Hypertension[NCT05275907] | Phase 4 | 0 participants (Actual) | Interventional | 2022-07-12 | Withdrawn (stopped due to Screened participants did not meet inclusion criteria prior to study completion date) | ||
| A Double-blind, Randomized, Multicenter, Parallel Group Study to Evaluate the Efficacy, Tolerability, and Safety of Treatment With the Combination of Valsartan/Amlodipine 160/5 mg Compared to Amlodipine 10 mg in Patients With Essential Hypertension Not Ad[NCT00437645] | Phase 3 | 1,183 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| Prevalence and Incidence of Dyskalemia in Hypertensive Patients Initiating a Fixed Dose Combination Pill of Telmisartan and Amlodipine[NCT05155436] | Phase 4 | 1,090 participants (Actual) | Interventional | 2022-01-15 | Completed | ||
| A 6-Week Multi-center, Randomized, Double-Blind, Parallel Group Study Comparing the Efficacy of Amlodipine Besylate/Benazepril Versus Amlodipine in the Treatment of Severe Hypertension[NCT00136851] | Phase 4 | 259 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| Manidipine Versus Amlodipine in Patients With Hypertension: Effects on Peripheral Edema Evaluated by Bioimpedance Analysis[NCT03106597] | Phase 4 | 46 participants (Actual) | Interventional | 2015-08-20 | Terminated (stopped due to Difficulty in enrolling subjects) | ||
| A Randomized Clinical Trial to Evaluate the Effects of Multiple Doses of Amlodipine 10 mg on Pedal Edema Measurements in Middle-Aged and Elderly Healthy Subjects and Patient With Hypertension[NCT00789321] | Phase 1 | 47 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| Fixed-Dose Combination of Perindopril/Amlodipine (Amlessa®) and Fixed-Dose Combination of Perindopril/Indapamide /Amlodipine (Co-Amlessa®) - Contribution to Management in Newly Diagnosed and Uncontrolled Hypertensive Patients[NCT03738761] | Phase 4 | 471 participants (Actual) | Interventional | 2018-02-13 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Blood pressure (BP) was measured at trough (24±3 hours post-dose). The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. If there was < 0. 5 mmHg difference in BP between the 2 arms, the non-dominant arm was used. At each visit, after the patient was in a sitting position with the back supported and both feet placed on the floor for 5 minutes, systolic and diastolic BP were measured 3 times with an automated BP monitor and appropriate size cuff. Means of the 3 measurements were calculated. A negative change indicates lowered BP. (NCT00437645)
Timeframe: Baseline to Week 8
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Valsartan/Amlodipine 160/5 mg | -4.65 |
| Amlodipine 10 mg | -4.13 |
Blood pressure (BP) was measured at trough (24±3 hours post-dose). The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. If there was < 0. 5 mmHg difference in BP between the 2 arms, the non-dominant arm was used. At each visit, after the patient was in a sitting position with the back supported and both feet placed on the floor for 5 minutes, systolic and diastolic BP were measured 3 times with an automated BP monitor and appropriate size cuff. Means of the 3 measurements were calculated. A negative change indicates lowered BP. (NCT00437645)
Timeframe: Baseline to Week 8
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Valsartan/Amlodipine 160/5 mg | -8.01 |
| Amlodipine 10 mg | -6.30 |
Only occurrences of peripheral edema quantified as a reported adverse event coded as peripheral edema were included in the analysis. If a patient experienced more than one occurrence of peripheral edema between Day 1 and Week 8, it was only counted once in the analysis. (NCT00437645)
Timeframe: Baseline to Week 8
| Intervention | Percentage of patients (Number) |
|---|---|
| Valsartan/Amlodipine 160/5 mg | 6.6 |
| Amlodipine 10 mg | 31.1 |
Blood pressure (BP) was measured at trough (24±3 hours post-dose). The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. If there was < 0. 5 mmHg difference in BP between the 2 arms, the non-dominant arm was used. At each visit, after the patient was in a sitting position with the back supported and both feet placed on the floor for 5 minutes, systolic and diastolic BP were measured 3 times with an automated BP monitor and appropriate size cuff. Means of the 3 measurements were calculated. A negative change indicates lowered BP. (NCT00437645)
Timeframe: Baseline to Weeks 4, 8, and 12
| Intervention | mmHg (Least Squares Mean) | |||||
|---|---|---|---|---|---|---|
| msSBP: Week 4 (n=576, 535) | msSBP: Week 8 (n=567, 510) | msSBP: Week 12 (n=569, 531) | msDBP: Week 4 (n=576, 535) | msDBP: Week 8 (n=576, 510) | msDBP: Week 12 (n=569, 531) | |
| Amlodipine 10 mg | -6.48 | -6.11 | -7.82 | -4.23 | -3.97 | -4.90 |
| Valsartan/Amlodipine 160/5 mg | -8.40 | -8.15 | -9.08 | -5.05 | -4.68 | -5.50 |
Systolic response was defined as msSBP < 130 mmHg or at least a 20 mmHg reduction from baseline in msSBP at Weeks 4, 8, and 12. Blood pressure (BP) was measured at trough (24±3 hours post-dose). The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. At each visit, after the patient was in a sitting position with the back supported and both feet placed on the floor for 5 minutes, systolic and diastolic BP were measured 3 times with an automated BP monitor and appropriate size cuff. Means of the 3 measurements were calculated. (NCT00437645)
Timeframe: Baseline to Weeks 4, 8, and 12
| Intervention | Percentage of patients (Number) | ||
|---|---|---|---|
| Week 4 (n=576, 535) | Week 8 (n=567, 510) | Week 12 (n=569, 531) | |
| Amlodipine 10 mg | 25.42 | 25.49 | 31.26 |
| Valsartan/Amlodipine 160/5 mg | 35.07 | 34.22 | 37.96 |
Least Squares Mean Difference from Baseline (NCT00789321)
Timeframe: Baseline and 2 weeks
| Intervention | Grams (Least Squares Mean) |
|---|---|
| Amlodipine 10 Milligrams | 44.8 |
| Placebo | 5.8 |
Segmental biomimpedance was measured using a multifrequency analyzer (ImpediMed SFB7). The device was used to measure impedance (measured in Ohms) of a small current traveling between leads placed at the ankle and knee. Least Squares Mean Difference from Baseline in impedance is the primary endpoint. (NCT00789321)
Timeframe: Baseline and 2 weeks
| Intervention | Ohms (Least Squares Mean) |
|---|---|
| Amlodipine 10 Milligrams | -7.9 |
| Placebo | 3.8 |
7 reviews available for amlodipine and Edema
| Article | Year |
|---|---|
Topics: Amlodipine; Ankle; Calcium Channel Blockers; Drug-Related Side Effects and Adverse Reactions; Edema; | 2023 |
Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion-dependent beta thalassaemia.
Topics: Amlodipine; beta-Thalassemia; Calcium Channel Blockers; Cardiomyopathies; Child; Edema; Ferritins; H | 2023 |
Perindopril arginine and amlodipine besylate for hypertension: a safety evaluation.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Cough; Dose-Response Relationship, Drug; Drug C | 2018 |
Peripheral edema and headache associated with amlodipine treatment: a meta-analysis of randomized, placebo-controlled trials.
Topics: Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Edema; Headache; Humans; Hypertension | 2019 |
Mitigation of calcium channel blocker-related oedema in hypertension by antagonists of the renin-angiotensin system.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antih | 2009 |
Efficacy and safety profiles of manidipine compared with amlodipine: a meta-analysis of head-to-head trials.
Topics: Adult; Amlodipine; Ankle; Antihypertensive Agents; Blood Pressure; Dihydropyridines; Edema; Humans; | 2011 |
Evolution of calcium antagonists: past, present, and future.
Topics: Amlodipine; Calcium Channel Blockers; Diabetic Angiopathies; Edema; Humans; Hypertension; Hypertroph | 2003 |
45 trials available for amlodipine and Edema
| Article | Year |
|---|---|
Efficacy and tolerability between an olmesartan/amlodipine fixed-dose combination and an amlodipine double dose in mild to moderate hypertension.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Edema; | 2013 |
Efficacy and safety of perindopril arginine + amlodipine in hypertension.
Topics: Amlodipine; Antihypertensive Agents; Diabetes Mellitus; Double-Blind Method; Drug Therapy, Combinati | 2015 |
Leg edema with (S)-amlodipine vs conventional amlodipine given in triple therapy for hypertension: a randomized double blind controlled clinical trial.
Topics: Adult; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure | 2016 |
Chlorthalidone Versus Amlodipine for Hypertension in Kidney Transplant Recipients Treated With Tacrolimus: A Randomized Crossover Trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Chlorthalidone; Cr | 2017 |
Chlorthalidone Versus Amlodipine for Hypertension in Kidney Transplant Recipients Treated With Tacrolimus: A Randomized Crossover Trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Chlorthalidone; Cr | 2017 |
Chlorthalidone Versus Amlodipine for Hypertension in Kidney Transplant Recipients Treated With Tacrolimus: A Randomized Crossover Trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Chlorthalidone; Cr | 2017 |
Chlorthalidone Versus Amlodipine for Hypertension in Kidney Transplant Recipients Treated With Tacrolimus: A Randomized Crossover Trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Chlorthalidone; Cr | 2017 |
An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study.
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pr | 2008 |
The Phase III, double-blind, parallel-group controlled study of amlodipine 10 mg once daily in Japanese patients with essential hypertension who insufficiently responded to amlodipine 5 mg once daily.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Dose-Res | 2009 |
The combination of amlodipine/valsartan 5/160 mg produces less peripheral oedema than amlodipine 10 mg in hypertensive patients not adequately controlled with amlodipine 5 mg.
Topics: Aged; Amlodipine; Antihypertensive Agents; Drug Combinations; Edema; Female; Humans; Hypertension; M | 2009 |
Combination of amlodipine and enalapril in hypertensive patients with coronary disease.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Coronary Disease; Drug Therapy, Combination; Ed | 2009 |
Results of treatment with telmisartan-amlodipine in hypertensive patients.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoa | 2009 |
Comparative efficacy and safety of amlodipine/benazepril combination therapy and amlodipine monotherapy in severe hypertension.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Benzazepines; Chron | 2010 |
Effect of valsartan or olmesartan addition to amlodipine on ankle edema in hypertensive patients.
Topics: Adult; Aged; Amlodipine; Ankle Joint; Antihypertensive Agents; Blood Pressure; Cross-Over Studies; D | 2010 |
Comparison of changes of body water measured by using bioelectrical impedance analysis between lercanidipine and amlodipine therapy in hypertensive outpatients.
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Body Composition; Body Water; Dihydrop | 2010 |
Effect of aliskiren addition to amlodipine on ankle edema in hypertensive patients: a three-way crossover study.
Topics: Amides; Amlodipine; Ankle; Ankle Joint; Antihypertensive Agents; Blood Pressure; Calcium Channel Blo | 2011 |
Comparative efficacy and safety of combination aliskiren/amlodipine and amlodipine monotherapy in African Americans with stage 2 hypertension.
Topics: Adult; Amides; Amlodipine; Black or African American; Blood Pressure; Blood Pressure Monitoring, Amb | 2011 |
Effect of telmisartan addition to amlodipine on ankle edema development in treating hypertensive patients.
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Ankle; Antihypertensive Agents; B | 2011 |
Segmental bioimpedance for measuring amlodipine-induced pedal edema: a placebo-controlled study.
Topics: Amlodipine; Antihypertensive Agents; Edema; Electric Impedance; Female; Humans; Male; Middle Aged | 2012 |
Segmental bioimpedance for measuring amlodipine-induced pedal edema: a placebo-controlled study.
Topics: Amlodipine; Antihypertensive Agents; Edema; Electric Impedance; Female; Humans; Male; Middle Aged | 2012 |
Segmental bioimpedance for measuring amlodipine-induced pedal edema: a placebo-controlled study.
Topics: Amlodipine; Antihypertensive Agents; Edema; Electric Impedance; Female; Humans; Male; Middle Aged | 2012 |
Segmental bioimpedance for measuring amlodipine-induced pedal edema: a placebo-controlled study.
Topics: Amlodipine; Antihypertensive Agents; Edema; Electric Impedance; Female; Humans; Male; Middle Aged | 2012 |
Segmental bioimpedance for measuring amlodipine-induced pedal edema: a placebo-controlled study.
Topics: Amlodipine; Antihypertensive Agents; Edema; Electric Impedance; Female; Humans; Male; Middle Aged | 2012 |
Segmental bioimpedance for measuring amlodipine-induced pedal edema: a placebo-controlled study.
Topics: Amlodipine; Antihypertensive Agents; Edema; Electric Impedance; Female; Humans; Male; Middle Aged | 2012 |
Segmental bioimpedance for measuring amlodipine-induced pedal edema: a placebo-controlled study.
Topics: Amlodipine; Antihypertensive Agents; Edema; Electric Impedance; Female; Humans; Male; Middle Aged | 2012 |
Segmental bioimpedance for measuring amlodipine-induced pedal edema: a placebo-controlled study.
Topics: Amlodipine; Antihypertensive Agents; Edema; Electric Impedance; Female; Humans; Male; Middle Aged | 2012 |
Segmental bioimpedance for measuring amlodipine-induced pedal edema: a placebo-controlled study.
Topics: Amlodipine; Antihypertensive Agents; Edema; Electric Impedance; Female; Humans; Male; Middle Aged | 2012 |
Quantification of pedal edema during treatment with S(-)-amlodipine nicotinate versus amlodipine besylate in female Korean patients with mild to moderate hypertension: a 12-week, multicenter, randomized, double-blind, active-controlled, phase IV clinical
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Dose-Response R | 2012 |
Nebivolol vs amlodipine as first-line treatment of essential arterial hypertension in the elderly.
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Benzopyrans; Blood Pressure; Double-Bl | 2002 |
Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives.
Topics: Aged; Amlodipine; Calcium Channel Blockers; Dihydropyridines; Double-Blind Method; Drug Therapy, Com | 2002 |
Effect of benazepril addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients.
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Ankle; Benzazepines; Calcium Chan | 2003 |
Quantification of leg oedema in postmenopausal hypertensive patients treated with lercanidipine or amlodipine.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Volume; Calcium Channel Blockers; D | 2003 |
Heterogeneous effect of calcium antagonists on leg oedema: a comparison of amlodipine versus lercanidipine in hypertensive patients.
Topics: Adult; Amlodipine; Blood Pressure; Calcium Channel Blockers; Cross-Over Studies; Dihydropyridines; E | 2003 |
Efficacy and tolerability of the combination valsartan/hydrochlorothiazide compared with amlodipine in a mild-to-moderately hypertensive Brazilian population.
Topics: Aged; Amlodipine; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Brazil; Double-Blind Method | 2003 |
Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension.
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazep | 2004 |
Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients.
Topics: Adult; Age Factors; Aged; Amlodipine; Ankle; Blood Pressure; Cross-Over Studies; Drug Therapy, Combi | 2007 |
Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hyperten
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Double-Blind Method; | 2007 |
Efficacy and tolerability of candesartan cilexetil/hydrochlorothiazide and amlodipine in patients with poorly controlled mild-to-moderate essential hypertension.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; | 2007 |
Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stag
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzo | 2007 |
At equipotent doses, isradipine is better tolerated than amlodipine in patients with mild-to-moderate hypertension: a double-blind, randomized, parallel-group study.
Topics: Adult; Aged; Amlodipine; Ankle; Belgium; Blood Pressure; Delayed-Action Preparations; Double-Blind M | 1994 |
Randomized placebo-controlled trial of amlodipine in vasospastic angina. Amlodipine Study 160 Group.
Topics: Adult; Aged; Amlodipine; Angina Pectoris, Variant; Double-Blind Method; Edema; Female; Humans; Male; | 1993 |
Amlodipine versus atenolol in essential hypertension.
Topics: Adolescent; Adult; Aged; Amlodipine; Atenolol; Blood Pressure; Double-Blind Method; Drug Administrat | 1994 |
Early side-effects of antihypertensive therapy: comparison of amlodipine and nifedipine retard.
Topics: Adult; Aged; Amlodipine; Delayed-Action Preparations; Dizziness; Double-Blind Method; Edema; Female; | 1993 |
Sex- and age-related antihypertensive effects of amlodipine. The Amlodipine Cardiovascular Community Trial Study Group.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Black People; Bloo | 1996 |
-Efficacy and safety of using amlodipine in treatment of mild and moderate essential hypertension-.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Dizziness; Drug Administration Schedule; Edema; Fe | 1995 |
Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine.
Topics: Adult; Aged; Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; | 1996 |
Mibefradil in the treatment of systemic hypertension: comparative studies with other calcium antagonists.
Topics: Adult; Aged; Amlodipine; Benzimidazoles; Calcium Channel Blockers; Diltiazem; Double-Blind Method; E | 1997 |
Improved tolerability of felodipine compared with amlodipine in elderly hypertensives: a randomised, double-blind study in 535 patients, focusing on vasodilatory adverse events. The International Study Group.
Topics: Aged; Amlodipine; Antihypertensive Agents; Delayed-Action Preparations; Dizziness; Double-Blind Meth | 1998 |
Amlodipine, enalapril, and dependent leg edema in essential hypertension.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Diastole; Dose-Response Relationsh | 2000 |
Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. Comparison of Candesartan and Amlodipine for Safety, Tolerability and Efficacy (CASTLE) Study Investigators.
Topics: Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Calcium Cha | 2001 |
Ankle edema formation during treatment with the calcium channel blockers lacidipine and amlodipine: a single-centre study.
Topics: Adolescent; Adult; Aged; Amlodipine; Ankle; Blood Pressure; Calcium Channel Blockers; Dihydropyridin | 2000 |
A double-blind, parallel-group study of amlodipine versus long-acting nitrate in the management of elderly patients with stable angina.
Topics: Aged; Aged, 80 and over; Amlodipine; Angina Pectoris; Blood Pressure; Calcium Channel Blockers; Dela | 2001 |
Combination therapy of amlodipine/benazepril versus monotherapy of amlodipine in a practice-based setting.
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Calcium Channel Blo | 2002 |
A study of the efficacy and safety of amlodipine for the treatment of hypertension in general practice.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Calcium Channel Blockers; Edema; Female; Headache; Human | 1991 |
Efficacy and safety of amlodipine in vasospastic angina: an interim report of a multicenter, placebo-controlled trial. The Investigators of Study 160.
Topics: Amlodipine; Angina Pectoris; Calcium Channel Blockers; Clinical Trials as Topic; Coronary Vasospasm; | 1989 |
The safety of amlodipine.
Topics: Adrenergic beta-Antagonists; Aged; Amlodipine; Calcium Channel Blockers; Clinical Trials as Topic; D | 1989 |
24 other studies available for amlodipine and Edema
| Article | Year |
|---|---|
Cilnidipine for Amlodipine Induced Pedal Edema and its Anti-hypertensive Effect in a Tertiary Care Teaching Hospital of Western Nepal.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pressure; Dihydropyridine | 2021 |
Amlodipine Induced Massive Ascites, a Rare Clinical Case.
Topics: Adult; Amlodipine; Ascites; Calcium Channel Blockers; Edema; Humans; Hypertension; Male | 2020 |
More Than Meets the Eye: A Patient with Hand Swelling and Newly Diagnosed Diabetes Mellitus.
Topics: Aged; Amlodipine; Anemia; Antihypertensive Agents; Blood Sedimentation; C-Reactive Protein; Diabetes | 2021 |
Amlodipine: The double edged sword.
Topics: Age Factors; Amlodipine; Blood Pressure Determination; Calcium Channel Blockers; Child; Child, Presc | 2017 |
Successful re-administration of Pazopanib in a patient with metastatic renal cell carcinoma and a history of Pazopanib-induced nephrotic syndrome: a case report.
Topics: Aged; Amlodipine; Angiogenesis Inhibitors; Antihypertensive Agents; Antineoplastic Agents; Carcinoma | 2019 |
Generalised peripheral oedema associated with amlodipine therapy in two dogs.
Topics: Amlodipine; Animals; Antihypertensive Agents; Dog Diseases; Dogs; Edema; Female; Hypertension | 2013 |
Clinical Effectiveness, Safety and Tolerability of Amlodipine/Valsartan in Hypertensive Patients: the Indonesian Subset of the EXCITE Study.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Cough; Drug Combinations; Drug Sub | 2015 |
Switching from a Free Association of Perindopril/Amlodipine to a Fixed-Dose Combination: Increased Antihypertensive Efficacy and Tolerability.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Cohort Studies; Diabetes Mellitus, | 2016 |
Nicolau Syndrome.
Topics: Amlodipine; Ankle; Edema; Glucocorticoids; Heparin; Humans; Injections, Intramuscular; Male; Methylp | 2017 |
Re: Amlodipine for migraine prophylaxis.
Topics: Amlodipine; Dose-Response Relationship, Drug; Edema; Humans; Migraine Disorders; Time Factors; Vasod | 1999 |
Stasis dermatitis as a complication of amlodipine therapy.
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Carcinoma, B | 2009 |
Paraneoplastic Raynaud's phenomenon in a breast cancer survivor.
Topics: Adult; Amlodipine; Antibodies, Antinuclear; Antineoplastic Agents; Breast Neoplasms; Edema; Female; | 2010 |
Amlodipine besylate/olmesartan medoximil fixed combination for the treatment of hypertension.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; | 2009 |
Chronic conjunctival chemosis from amlodipine besylate (Norvasc).
Topics: Aged; Amlodipine; Antihypertensive Agents; Chronic Disease; Conjunctival Diseases; Edema; Foot Disea | 2011 |
Amlodipine/valsartan single-pill combination: a prospective, observational evaluation of the real-life safety and effectiveness in the routine treatment of hypertension.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Amlodipine, Valsartan Drug Combination; Antihypertensive | 2012 |
[Systemic sclerosis in a patient suffering from breast cancer].
Topics: Adult; Amlodipine; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Duct | 2012 |
Cyclosporin enhances the tendency towards oedema and flushing noted on dihydropyridine calcium channel blockers.
Topics: Adolescent; Adult; Amlodipine; Calcium Channel Blockers; Child; Child, Preschool; Cyclosporine; Dihy | 2002 |
Pedal edema--not all dihydropyridine calcium antagonists are created equal.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Edema; Humans; Hyper | 2002 |
Anasarca edema with amlodipine treatment.
Topics: Aged; Amlodipine; Edema; Female; Humans; Hypertension | 2005 |
Amlodipine-induced bilateral upper extremity edema.
Topics: Amlodipine; Antihypertensive Agents; Child; Edema; Female; Humans; Hypertension; Upper Extremity; Va | 2007 |
Sex- and age-related antihypertensive effects of amlodipine.
Topics: Aged; Aging; Amlodipine; Antihypertensive Agents; Edema; Female; Humans; Hypertension; Male; Middle | 1997 |
Different effects of calcium antagonists on fluid filtration of large arteries and albumin permeability in spontaneously hypertensive rats.
Topics: Amlodipine; Animals; Benzimidazoles; Blood Pressure; Calcium Channel Blockers; Capillary Permeabilit | 1998 |
Achilles tendonitis: an unusual complication of amlodipine therapy.
Topics: Achilles Tendon; Amlodipine; Ankle; Antihypertensive Agents; Calcium Channel Blockers; Edema; Humans | 1999 |
[A case of severe systemic edema in an elderly hypertensive patient with systemic lupus erythematodes during long-term treatment with anti-hypertensive drugs].
Topics: Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Bipheny | 2001 |